Nelson B. Moseley Ii

Array ( [id] => 17393405 [patent_doc_number] => 11242407 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => High-affinity anti-MERTK antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/801078 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 42 [patent_no_of_words] => 62619 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16484002 [patent_doc_number] => 20200377603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/799509 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59935 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012855 [patent_doc_number] => 20200181270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING SYSTEMIC MASTOCYTOSIS [patent_app_type] => utility [patent_app_number] => 16/796795 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -89 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206578 [patent_doc_number] => 20200239568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => HOMODIMERIC PROTEIN CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 16/784778 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16176961 [patent_doc_number] => 20200223929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/784166 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15927919 [patent_doc_number] => 20200155593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/773769 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18259767 [patent_doc_number] => 11607453 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-21 [patent_title] => Mesothelin binding proteins [patent_app_type] => utility [patent_app_number] => 16/773843 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 23847 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411785 [patent_doc_number] => 12077592 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => GPRC5D chimeric antigen receptors and cells expressing the same [patent_app_type] => utility [patent_app_number] => 16/743188 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 22 [patent_no_of_words] => 39232 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15740631 [patent_doc_number] => 20200109203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors [patent_app_type] => utility [patent_app_number] => 16/720623 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16720623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238305 [patent_doc_number] => 20200255539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => Anti-HER2 Antibodies and Immunoconjugates [patent_app_type] => utility [patent_app_number] => 16/721525 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16721525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065866 [patent_doc_number] => 20210268081 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-09-02 [patent_title] => TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS [patent_app_type] => utility [patent_app_number] => 16/719814 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065866 [patent_doc_number] => 20210268081 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-09-02 [patent_title] => TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS [patent_app_type] => utility [patent_app_number] => 16/719814 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090481 [patent_doc_number] => 20200199227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/719108 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895343 [patent_doc_number] => 20200147190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/715846 [patent_app_country] => US [patent_app_date] => 2019-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16715846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418627 [patent_doc_number] => 20230173085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => Saponin Conjugates [patent_app_type] => utility [patent_app_number] => 17/312311 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589737 [patent_doc_number] => 20200071403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => ANTI-LAG-3 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/687387 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15913053 [patent_doc_number] => 10653748 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins [patent_app_type] => utility [patent_app_number] => 16/678382 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 75 [patent_no_of_words] => 71945 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16678382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800143 [patent_doc_number] => 20200123214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => CSF1R-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 16/675475 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19955471 [patent_doc_number] => 12325879 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-10 [patent_title] => Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer [patent_app_type] => utility [patent_app_number] => 17/290172 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 34936 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316032 [patent_doc_number] => 12454574 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Anti-CD79B antibodies and chimeric antigen receptors and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/309144 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 15204 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309144 [rel_patent_id] =>[rel_patent_doc_number] =>)